In the past year alone, the industry has seen U.S. Food and Drug Administration (FDA) approval for numerous precision medicines, including two CAR-T cell therapies for blood cancers, a PD-1 inhibitor for microsatellite instability (known as MSI) high tumors, as well as targeted therapies for acute myeloid leukemia and cancers of the bladder, ovary, breast and lung.
In response to these needs, Cardinal Health Specialty Solutions released its third in-depth survey report, Oncology Insights, which details views on precision medicine from more than 160 U.S. oncologists nationwide. The report also assesses the availability of genomic testing and the current role it plays in the diagnosis and treatment of cancer.
Here are key insights from the report, which reveal both aspirations and hesitations from oncologists, regarding the growth of precision medicine. Click to continue>>
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
